Evidence map›Paper›PMID 38236416›Full record

ArticleJournal of medicinal chemistry2024

Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced Mortality.

Yuanguang Chen, Jianwen Sun, Hua Tong, Jieru Wang, Ruolin Cao, Huashen Xu, Lu Chen, Christophe Morisseau, Maoying Zhang, Yajie Shi and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. The Roles of EETs in Neurological Disorders.CNS neuroscience & therapeutics · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Yuanguang ChenKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jianwen SunKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hua TongLiaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jieru WangKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Ruolin CaoKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Huashen XuKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Lu ChenKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Christophe MorisseauDepartment of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.ORCID 0000-0002-5672-6631
Maoying ZhangKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yajie ShiKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Chao HanKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Junning ZhuangKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yongkui JingLiaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China.ORCID 0000-0002-7915-8593
Zhongbo LiuSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bruce D HammockDepartment of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.ORCID 0000-0003-1408-8317
Guoliang ChenKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.ORCID 0000-0003-3674-5226
Shenyang Pharmaceutical University · CNUC Davis Comprehensive Cancer Center

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
UC Davis CounterACT Center of Excellence: Developing Therapeutic Strategies for Mitigating the Chronic Neurological Consequences of Acute Organophosphate IntoxicationU54NS127758 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Amy R. Brooks-Kayal, Pamela J Lein · 2022 to 2026
$17.2M
Supplement for bioactive lipids as effectors and indicators of the deleterious effects of human healthR35ES030443 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORISSEAU, CHRISTOPHE HP · 2019 to 2025
$5.8M
NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R35 ES030443NINDS NIH HHS U54 NS127758
6 · The paper itself

Abstract

Epoxyeicosatrienoic acids with anti-inflammatory effects are inactivated by soluble epoxide hydrolase (sEH). Both sEH and histone deacetylase 6 (HDAC6) inhibitors are being developed as neuropathic pain relieving agents. Based on the structural similarity, we designed a new group of compounds with inhibition of both HDAC6 and sEH and obtained compound

Indexed as

LipopolysaccharidesNeuralgiaAnalgesicsAnimalsEpoxide HydrolasesGabapentinHistone Deacetylase 6Histone Deacetylase InhibitorsMiceAnalgesicsEpoxide HydrolasesGabapentinHistone Deacetylase 6Histone Deacetylase InhibitorsLipopolysaccharides

Identifiers

PMID38236416
PMCPMC11308793
OpenAlexW4390986038

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.